Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways

References

• Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000;105:3–7.
   PubMed Web of Science ®Google Scholar
• Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004;30:193–204.
   PubMed Web of Science ®Google Scholar
• O'Hare T, Walters DK, Stoffregen EP, . In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500–4505.
   PubMed Web of Science ®Google Scholar
• Marcucci G, Perrotti D, Caligiuri MA. Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin. Cancer Res., 9: 1333–1337, 2003. Clin Cancer Res 2003;9:1248–1252.
   Google Scholar
• Mahon FX, Deininger MW, Schultheis B, . Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000;96:1070–1079.
   PubMed Web of Science ®Google Scholar
• Gorre ME, Mohammed M, Ellwood K, . Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876–880.
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003;4:75–85.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Rosee PL, Muller MC, Ernst T, Cross NC. Impact of BCR-ABL mutations on patients with chronic myeloid leukemia. Cell Cycle 2011;10:250–260.
   PubMed Web of Science ®Google Scholar
• O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007;110:2242–2249.
   PubMed Web of Science ®Google Scholar
• le Coutre P, Tassi E, Varella-Garcia M, . Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000;95:1758–1766.
   PubMed Web of Science ®Google Scholar
• Campbell LJ, Patsouris C, Rayeroux KC, Somana K, Januszewicz EH, Szer J. BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration. Cancer Genet Cytogenet 2002;139:30–33.
   PubMed Web of Science ®Google Scholar
• Burger H, van Tol H, Brok M, . Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther 2005;4:747–752.
   PubMed Web of Science ®Google Scholar
• Hamada A, Miyano H, Watanabe H, Saito H. Interaction of imatinib mesilate with human P-glycoprotein. J Pharmacol Exp Ther 2003;307:824–828.
   PubMed Web of Science ®Google Scholar
• Illmer T, Schaich M, Platzbecker U, . P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004;18:401–408.
   PubMed Web of Science ®Google Scholar
• Ozvegy-Laczka C, Hegedus T, Varady G, . High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 2004;65:1485–1495.
   PubMed Web of Science ®Google Scholar
• Burger H, van Tol H, Boersma AW, . Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 2004;104:2940–2942.
   PubMed Web of Science ®Google Scholar
• Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004;104:3739–3745.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Belloc F, Lagarde V, . MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003;101:2368–2373.
   PubMed Web of Science ®Google Scholar
• Mohamed AN, Pemberton P, Zonder J, Schiffer CA. The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin Cancer Res 2003;9:1333–1337.
   PubMed Web of Science ®Google Scholar
• White D, Dang P, Venables A, . ABCB1 overexpression may predispose imatinib treated CML patients to the development of Abl kinase domain mutations, and may be an important contributor to acquired resistance. Blood 2006;108(Suppl. 1): Abstract 2144.
   Google Scholar
• Barnes DJ, Palaiologou D, Panousopoulou E, . Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res 2005;65:8912–8919.
   PubMed Web of Science ®Google Scholar
• Yuan H, Wang Z, Gao C, . BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia. J Biol Chem 2010;285:5085–5096.
   PubMed Web of Science ®Google Scholar
• White D, Saunders V, Lyons AB, . In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 2005;106:2520–2526.
   PubMed Web of Science ®Google Scholar
• White DL, Saunders VA, Dang P, . OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006;108:697–704.
   PubMed Web of Science ®Google Scholar
• Branford S, Hughes TP, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol 1999;107:587–599.
   PubMed Web of Science ®Google Scholar
• Branford S, Rudzki Z, Walsh S, . Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003;102:276–283.
   PubMed Web of Science ®Google Scholar
• Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005;44:879–894.
   PubMed Web of Science ®Google Scholar
• Shah NP, Kasap C, Weier C, . Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 2008;14:485–493.
   PubMed Web of Science ®Google Scholar
• Marie JP, Faussat-Suberville AM, Zhou D, Zittoun R. Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr1 expression. Leukemia 1993;7:825–831.
   PubMed Web of Science ®Google Scholar
• Tsuruo T, Iida-Saito H, Kawabata H, Oh-Hara T, Hamada H, Utakoji T. Characteristics of resistance to adriamycin in human myelogenous leukemia K562 resistant to adriamycin and in isolated clones. Jpn J Cancer Res 1986;77:682–692.
   PubMedGoogle Scholar
• Two new agents effective in Gleevec-resistant CML. Cancer Biol Ther 2004;3:1198–1199.
   PubMed Web of Science ®Google Scholar
• Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399–401.
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley PW, Breitenstein W, . Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129–141.
   PubMed Web of Science ®Google Scholar
• Branford S, Melo JV, Hughes TP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR–ABL mutation status really matter? Blood 2009;114:5426–5435.
   PubMed Web of Science ®Google Scholar
• Branford S, Rudzki Z, Parkinson I, . Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004;104:2926–2932.
   PubMed Web of Science ®Google Scholar
• Press RD, Willis SG, Laudadio J, Mauro MJ, Deininger MW. Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. Blood 2009;114:2598–2605.
   PubMed Web of Science ®Google Scholar
• Hahn PJ. Molecular biology of double-minute chromosomes. Bioessays 1993;15:477–484.
   PubMed Web of Science ®Google Scholar
• Balaban-Malenbaum G, Gilbert F. Double minute chromosomes and the homogeneously staining regions in chromosomes of a human neuroblastoma cell line. Science 1977;198:739–741.
   PubMed Web of Science ®Google Scholar
• Vogt N, Lefevre SH, Apiou F, . Molecular structure of double-minute chromosomes bearing amplified copies of the epidermal growth factor receptor gene in gliomas. Proc Natl Acad Sci USA 2004;101:11368–11373.
   PubMed Web of Science ®Google Scholar
• Schwab M. Oncogene amplification in solid tumors. Semin Cancer Biol 1999;9:319–325.
   PubMed Web of Science ®Google Scholar
• Sattler M, Verma S, Shrikhande G, . The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem 2000;275:24273–24278.
   PubMed Web of Science ®Google Scholar
• Penserga ET, Skorski T. Fusion tyrosine kinases: a result and cause of genomic instability. Oncogene 2007;26:11–20.
   PubMed Web of Science ®Google Scholar
• Nowicki MO, Falinski R, Koptyra M, . BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 2004;104:3746–3753.
   PubMed Web of Science ®Google Scholar
• Jiang X, Saw KM, Eaves A, Eaves C. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst 2007;99:680–693.
   PubMed Web of Science ®Google Scholar
• Morel F, Bris MJ, Herry A, . Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib. Eur J Haematol 2003;70:235–239.
   PubMed Web of Science ®Google Scholar
• Keeshan K, Mills KI, Cotter TG, McKenna SL. Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype. Leukemia 2001;15:1823–1833.
   PubMed Web of Science ®Google Scholar